Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 716 full-time employees. The company went IPO on 2018-06-28. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The firm provides more than 7.1 million treatments to over 1,95,000 patients.
Follow-Up Questions
Who is the CEO of Neuronetics Inc?
Mr. Keith Sullivan is the President of Neuronetics Inc, joining the firm since 2020.
What is the price performance of STIM stock?
The current price of STIM is $2.81, it has decreased 2.05% in the last trading day.
What are the primary business themes or industries for Neuronetics Inc?
Neuronetics Inc belongs to Health Care industry and the sector is Health Care
What is Neuronetics Inc market cap?
Neuronetics Inc's current market cap is $185.8M
Is Neuronetics Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Neuronetics Inc, including 2 strong buy, 6 buy, 1 hold, 0 sell, and 2 strong sell
